Alpine Immune Sciences announces $150M common stock offering

Alpine Immune Sciences announced that it has commenced an underwritten public offering of $150M of shares of its common stock pursuant to its existing shelf registration statement. Morgan Stanley, TD Cowen and Leerink Partners are acting as joint book-running managers for the proposed public offering. RBC Capital Markets is acting as a bookrunner and Oppenheimer & Co. and H.C. Wainwright & Co. are acting as co-lead managers for the proposed public offering.